[Guidelines for pharmacological primary prevention of cardiovascular diseases--who should be treated?]
- PMID: 12448268
[Guidelines for pharmacological primary prevention of cardiovascular diseases--who should be treated?]
Abstract
Background: Several clinical practice guidelines for the treatment of hypertension and hypercholesterolaemia are available. The quality of these guidelines varies and the basis for their conclusions is often not clear. We have used systematic and explicit methods in the development of a new set of recommendations. This is the first of three articles describing these guidelines.
Material and methods: Evidence was found by a systematic search in databases and reference lists in guidelines and articles. A set of recommendations was prepared based on a critical appraisal of the literature. These recommendations were revised through discussions with a panel of physicians and agreed upon after several iterations. The guidelines were circulated to professional, governmental and patient organisations, with a request for feedback on errors or shortcomings.
Results and interpretation: The absolute risk of cardiovascular disease should be used as the basis for discussing with a patient whether drug treatment should be initiated. A 20% risk of developing angina or myocardial infarction over the next ten years is a reasonable threshold for considering treatment. The effects of antihypertensives for persons older than 80 years and of cholesterol-lowering drugs for persons older than 70 years are uncertain. Treatment of blood pressure above 170/100 mm Hg is recommended independent of the risk of cardiovascular disease.
Comment in
-
[Practice guidelines and sense of guidelines].Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2255. Tidsskr Nor Laegeforen. 2002. PMID: 12448260 Norwegian. No abstract available.
-
[Guidelines are based on subjective view and choice of values].Tidsskr Nor Laegeforen. 2002 Nov 20;122(28):2727; author reply 2727. Tidsskr Nor Laegeforen. 2002. PMID: 12523096 Norwegian. No abstract available.
Similar articles
-
[Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease?].Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2287-8. Tidsskr Nor Laegeforen. 2002. PMID: 12448270 Review. Norwegian.
-
[Which antihypertensive drugs should be used in the primary prevention of cardiovascular disease?].Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2283-6. Tidsskr Nor Laegeforen. 2002. PMID: 12448269 Review. Norwegian.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001. J Am Coll Cardiol. 2004. PMID: 15358046 Review.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E. Arterioscler Thromb Vasc Biol. 2004. PMID: 15297292 Review.
-
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.Can J Cardiol. 2004 Jan;20(1):41-54. Can J Cardiol. 2004. PMID: 14968142
Cited by
-
The effect of how outcomes are framed on decisions about whether to take antihypertensive medication: a randomized trial.PLoS One. 2010 Mar 1;5(3):e9469. doi: 10.1371/journal.pone.0009469. PLoS One. 2010. PMID: 20209127 Free PMC article. Clinical Trial.
-
Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230].BMC Health Serv Res. 2003 Feb 27;3(1):5. doi: 10.1186/1472-6963-3-5. Epub 2003 Feb 27. BMC Health Serv Res. 2003. PMID: 12657163 Free PMC article. Clinical Trial.
-
Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention.PLoS Med. 2006 Jun;3(6):e134. doi: 10.1371/journal.pmed.0030134. PLoS Med. 2006. PMID: 16737346 Free PMC article. Clinical Trial.
-
Improving prescribing of antihypertensive and cholesterol-lowering drugs: a method for identifying and addressing barriers to change.BMC Health Serv Res. 2004 Sep 3;4(1):23. doi: 10.1186/1472-6963-4-23. BMC Health Serv Res. 2004. PMID: 15347426 Free PMC article. Clinical Trial.